Anixa Biosciences (ANIX) Return on Sales (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly Return on Sales came in at 1651.95% in Q4 2023, down 16.54% on a QoQ basis from 1417.54% in Q3 2023.

Anixa Biosciences (ANIX) Return on Sales (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of Return on Sales data on file, last reported at 1651.95% in Q4 2023.

Quarterly Return on Sales changed N/A year-over-year to 1651.95% in Q4 2023, while the trailing twelve-month figure through Oct 2023 was 1651.95% (changed N/A YoY) and the FY2023 annual result came in at 1643.43%, changed N/A from the prior year.
Return on Sales declined to 1651.95% in Q4 2023, from 1417.54% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 40.77% in Q4 2021 to a low of 1651.95% in Q4 2023.
A 3-year average of 303.08% and a median of 0.35% in 2021 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 8 bps in 2019, down 34 bps in 2019.
Tracing ANIX's Return on Sales over 3 years: stood at 0.47% in 2019, then jumped by 8725 bps to 40.77% in 2021, then sank by 4152 bps to 1651.95% in 2023.
The last three Return on Sales figures came in at 1651.95% (Q4 2023), 1417.54% (Q3 2023), and 0.33% (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	0.00%
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	0.00%
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	0.00%
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	0.00%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.00%
10	Anixa Biosciences	125.30 Mn	125.30 Mn	-	-

Download Data